• LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0000
  • Day Range
    ---
  • 52 Week Range
    Low 0.0001
    ---
    High 0.0001
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRGDXQ
Response Genetics Inc
40.0
0.0x
---
United StatesAVTX
Avalo Therapeutics Inc
3.8M
0.0x
---
United StatesEMMA
Emmaus Life Sciences Inc
6.3M
-1.3x
---
United StatesNBY
NovaBay Pharmaceuticals Inc
3.3M
0.0x
---
United StatesPEARQ
Pear Therapeutics Inc
140.0
0.0x
---
United StatesIMPLQ
IPI Legacy Liquidation Co
181.6K
0.0x
---
As of 2024-03-28

Company Information

Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Contact Information

Headquarters
1640 Marengo St Fl 7thLOS ANGELES, CA, United States 90033-1057
Phone
323-224-3900
Fax
323-224-3096

Executives

Chairman of the Board, Chief Executive Officer
Thomas Bologna
Chief Financial Officer, Vice President
Kevin Harris
General Counsel
Adanech Getachew
Lead Independent Director
Kirk Calhoun
Director
Michael Serruya

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$40.00
Revenue (TTM)
$16.6M
Shares Outstanding
38.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.37
Book Value
$-0.03
P/E Ratio
0.0x
Price/Sales (TTM)
0.0
Price/Cash Flow (TTM)
---
Operating Margin
-79.26%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.